研究業績

  1. ホーム
  2. 業績
  3. 研究業績
  4. 2017年
  1. 2023年
  2. 2022年
  3. 2021年
  4. 2020年
  5. 2019年
  6. 2018年
  7. 2017年
  8. 2016年
  9. 2015年
  10. 2014年
  11. 2013年
  12. 2012年
  13. 2011年
  14. 2010年
  15. 2009年
  16. 2008年
  17. 2007年
  18. 2006年
  19. 2005年
  20. 2004年

2017年研究業績

英文原著

  1. The prevalence of cerebral microbleeds in HIV-infected hemophilia patients.Endo T, Goto H, Miyashita N, Ara T, Kasahara K, Okada K, Shiratori S, Sugita J, Onozawa M Hashimoto D, Nakagawa M, Kahata K, Fujimoto K, Kondo T, Hashino S, Houkin K, Teshima T. J AIDS Clin Res. 2017, 8: 747. doi: 10.4172/2155-6113.1000747
  2. "T-cell depletion effects of low-dose antithymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation."Shiratori S, Kosugi-Kanaya M, Hayase E, Okada K, Goto H, Sugita J, Onozawa M, Nakagawa M, Kahata K, Hashimoto D, Endo T, Kondo T, Teshima T. Transpl Immunol. 2017 Nov 8. pii: S0966-3274(17)30111-9. doi: 10.1016/j.trim.2017.11.001. [Epub ahead of print] No abstract available. PMID: 29128394"
  3. A novel heterozygous ITGB3 p.T720del inducing spontaneous activation of integrin αIIbβ3 in autosomal dominant macrothrombocytopenia with aggregation dysfunction. Naohiro Miyashita, Masahiro Onozawa, Koji Hayasaka, Takahiro Yamada, Ohsuke Migita, Kenichiro Hata, Kohei Okada, Hideki Goto, Masao Nakagawa, Daigo Hashimoto, Kaoru Kahata, Takeshi Kondo, Shinji Kunishima, Takanori Teshima Annals of Hematology IN PRESS
  4. Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, Komori D, Gershon P, Kiryu M, Tanzima S, Fukumoto K, Enami T, Muratani M, Yoshida K, Ogawa S, Matsue K, Nakamura N, Takeuchi K, Izutsu K, Fujimoto K, Teshima T, Miyoshi H, Gaulard P, Ohshima K, Chiba S. Leukemia. 2017 Aug 23. [Epub ahead of print]
  5. Altered oscillation of Doppler-derived renal and renal interlobar venous flow velocities in hypertensive and diabetic patients. Kudo Y, Mikami T, Nishida M, Okada K, Kaga S, Masauzi N, Omotehara S, Shibuya H, Kahata K, Shimizu C. J Med Ultrason (2001). 2017 Oct;44(4):305-314. doi: 10.1007/s10396-017-0770-0. Epub 2017 Feb 1. Erratum in: J Med Ultrason (2001). 2018 Jan;45(1):197.
  6. Autologous Haematopoietic Stem Cell Transplantation for Japanese Patients with Systemic Sclerosis: Long-term Follow-up on a Phase II trial and Treatment-related Fatal Cardiomyopathy. Nakamura H, Odani T, Yasuda S, Noguchi A, Fujieda Y, Kato M, Oku K, Bohgaki T, Sugita J, Endo T, Teshima T, Atsumi T. Mod Rheumatol. 2017 Dec 18:1-16. doi: 10.1080/14397595.2017.1416920. [Epub ahead of print] PMID: 29251023
  7. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, Waldmann TA, Perera PY. Am J Hematol. 2017 Sep;92(9):892-901. doi: 10.1002/ajh.24794. Epub 2017 Jun 5. PMID: 28543380
  8. Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older. Kawamura K, Kako S, Mizuta S, Ishiyama K, Aoki J, Yano S, Fukuda T, Uchida N, Ozawa Y, Eto T, Iwato K, Kanamori H, Kahata K, Kondo T, Sawa M, Ichinohe T, Atsuta Y, Kanda Y.
  9. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, Pittaluga S, Bamford RN, Nakagawa M, Ouyang ST, Epstein AL, Kadin ME, Del Mistro A, Woessner R, Jaffe ES, Waldmann TA. Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3975-3980. doi: 10.1073/pnas.1700682114. Epub 2017 Mar 29. PMID: 28356514
  10. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program. Miyamoto T, Fukuda T, Nakashima M, Henzan T, Kusakabe S, Kobayashi N, Sugita J, Mori T, Kurokawa M, Mori SI. Biol Blood Marrow Transplant. 2017 Jun;23(6):938-944. doi: 10.1016/j.bbmt.2017.02.012. Epub 2017 Feb 17. PMID: 28219836
  11. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: evaluation of drug-drug interactions mediated by organic anion transporter 3. Narumi K, Sato Y, Kobayashi M, Furugen A, Kasashi K, Yamada T, Teshima T, Iseki K. Biopharm Drug Dispos. 2017 Dec;38(9):501-508.
  12. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma. Tsutsumi Y, Nakayama C, Kamada K, Kikuchi R, Kudo D, Ito S, Matsuoka S, Shiratori S, Yamamoto Y, Naruse H, Teshima T. Ann Hematol. 2017 Sep 22. 2017 Dec; 96(12):2057-2061.
  13. GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Terakura S, Kuwatsuka Y, Yamasaki S, Wake A, Kanda J, Inamoto Y, Mizuta S, Yamaguchi T, Uchida N, Kouzai Y, Aotsuka N, Ogawa H, Kanamori H, Nishiwaki K, Miyakoshi S, Onizuka M, Amano I, Fukuda T, Ichinohe T, Atsuta Y, Murata M, Teshima T. Bone Marrow Transplant. 2017 Sep; 52(9):1261-1267.
  14. Hayase E, Hashimoto D, Nakamura K, Noizat C, Ogasawara R, Takahashi S, Ohigashi H, Yokoi Y, Sugimoto R, Matsuoka S, Ara T, Yokoyama E, Yamakawa T, Ebata K, Kondo T, Hiramine R, Aizawa T, Ogura Y, Hayashi T, Mori H, Kurokawa K, Tomizuka K, Ayabe T, Teshima T. R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease. J Exp Med. 2017 Dec 4; 214(12): 3507-3518.
  15. Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ito J, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. J Hepatol. 2017 Nov;67(5):1106-1108. doi: 10.1016/j.jhep.2017.04.008. Epub 2017 Apr 22. No abstract available. PMID: 28438688
  16. Horiguchi M, Fujioka M, Kondo T, Fujioka Y, Li X, Horiuchi K, O Satoh A, Nepal P, Nishide S, Nanbo A, Teshima T, and Ohba Y Improved FRET Biosensor for the Measurement of BCR-ABL Activity in Chronic Myeloid Leukemia Cells. Cell Struct Funct, 42: 15-26, 2017
  17. Ibata M, Iwasaki J, Fujioka Y, Nakagawa K, Darmanin S, Onozawa M, Hashimoto D, Ohba Y, Hatakeyama S, Teshima T, Kondo T. Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities. Cancer Sci. 2017 Feb;108(2): 200-207.
  18. Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults. Arai Y, Kondo T, Shigematsu A, Tanaka J, Ohashi K, Fukuda T, Hidaka M, Kobayashi N, Iwato K, Sakura T, Onizuka M, Ozawa Y, Eto T, Kurokawa M, Kahata K, Uchida N, Atsuta Y, Mizuta S, Kako S. Am J Hematol. 2018 Jan;93(1):47-57. doi: 10.1002/ajh.24933. Epub 2017 Nov 9.
  19. Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway. Lee SM, Park HY, Suh YS, Yoon EH, Kim J, Jang WH, Lee WS, Park SG, Choi IW, Choi I, Kang SW, Yun H, Teshima T, Kwon B, Seo SK. Proc Natl Acad Sci U S A. 2017 Jul 18; 114(29):E5881-E5890.
  20. Iriyama N, Kazuteru O, Hashino S, Kimura S, Nakaseko C, Takanao H, Hino M, Uchiyama Y, Morita S, Sakamoto J, Sakamaki H, Inokuchi K: Efficacy of reduced-dose dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: The LD-CML study of the Kanto CML Study. Internal Med 2017 Oct.
  21. Iyama S, Sato T, Ohnishi H, Kanisawa Y, Ohta S, Kondo T, Mori A, Tsutsumi Y, Kuroda H, Kakinoki Y, Yamamoto S, Takahashi T, Shindo M, Torimoto Y, Sato K, Iwasaki H, Haseyama Y, Kohda K, Nagamachi Y, Hirayama Y, Sakai H, Hirata Y, Fukuhara T, Ikeda H, Kobune M, Kato J, and Kurosawa M A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma. Clin Lymphoma Myeloma Leuk, 17: 23-30. e2, 2017
  22. Kanaya M, Hayashi Y, Hashimoto D, Endo T, Sugita J, Ohigashi H, Hashiguchi J, Matsukawa T, Matsuoka S, Kosugi-Kanaya M, Goto H, Onozawa M, Kahata K, Fujimoto K, Kondo T, Akizawa K, Shibuya H, Shimizu C, and Teshima T MALDI-TOF MS in post-transplant bloodstream infections: reliable identification of causative bacteria in the neutropenic phase. Bone Marrow Transplant, 52: 778-780, 2017
  23. Kondo T, Nagamura-Inoue T, Tojo A, Nagamura F, Uchida N, Nakamae H, Fukuda T, Mori T, Yano S, Kurokawa M, Ueno H, Kanamori H, Hashimoto H, Onizuka M, Takanashi M, Ichinohe T, Atsuta Y, and Ohashi K. Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. Am J Hematol, 92: 902-908, 2017
  24. Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities. Ibata M, Iwasaki J, Fujioka Y, Nakagawa K, Darmanin S, Onozawa M, Hashimoto D, Ohba Y, Hatakeyama S, Teshima T, Kondo T. Cancer Sci. 2017 Feb;108(2):200-207, 2017 Feb 28.
  25. MALDI-TOF MS in post-transplant bloodstream infections: reliable identification of causative bacteria in the neutropenic phase. Kanaya M, Hayashi Y, Hashimoto D, Endo T, Sugita J, Ohigashi H, Hashiguchi J, Matsukawa T, Matsuoka S, Kosugi-Kanaya M, Goto H, Onozawa M, Kahata K, Fujimoto K, Kondo T, Akizawa K, Shibuya H, Shimizu C, Teshima T. Bone Marrow Transplant. 2017 May;52(5):778-780. doi: 10.1038/bmt.2016.365. Epub 2017 Jan 30. No abstract available. PMID: 28134922
  26. Mizuha Kosugi-Kanaya, Satoshi Ueha, Jun Abe, Shigeyuki Shichino,Francis H. W. Shand, Teppei Morikawa, Makoto Kurachi, Yusuke Shono, Naoto Sudo, Ai Yamashita, Fumiko Suenaga, Akihiro Yokoyama, Wang Yong, Masahiro Imamura, Takanori Teshima and Kouji Matsushima (2017) Long-lasting graft-Derived Donor T cells contribute to the Pathogenesis of chronic graft-versus-host Disease in Mice. Front. Immunol. 8:1842.
  27. Phase II study of intrabone single unit cord blood transplantation for hematological malignancies. Murata M, Maeda Y, Masuko M, Onishi Y, Endo T, Terakura S, Ishikawa Y, Iriyama C, Ushijima Y, Goto T, Fujii N, Tanimoto M, Kobayashi H, Shibasaki Y, Fukuhara N, Inamoto Y, Suzuki R, Kodera Y, Matsushita T, Kiyoi H, Naoe T, Nishida T. Cancer Sci. 2017 Aug;108(8):1634-1639. doi: 10.1111/cas.13291. Epub 2017 Jun 29. PMID: 28582607
  28. Prior history of HLA-mismatched stem cell transplantation is a risk factor for graft failure in HLA-haploidentical transplantation. Sugita J, Miyamoto T, Kawashima N, Hatsumi N, Anzai N, Kaneko H, Nara M, Minauchi K, Harada M, Teshima T. Bone Marrow Transplant. 2017 Feb;52(2):323-325. doi: 10.1038/bmt.2016.278. Epub 2016 Nov 7. No abstract available. PMID: 27819686
  29. Quality of Life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease. Kurosawa S, Oshima K, Yamaguchi T, Yanagisawa A, Fukuda T, Kanamori H, Mori T, Takahashi S, Kondo T, Kohno A, Miyamura K, Umemoto Y, Teshima T, Taniguchi S, Yamashita T, Inamoto Y, Kanda Y, Okamoto S, Atsuta Y. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1749-1758.
  30. R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease. Hayase E, Hashimoto D, Nakamura K, Noizat C, Ogasawara R, Takahashi S, Ohigashi H, Yokoi Y, Sugimoto R, Matsuoka S, Ara T, Yokoyama E, Yamakawa T, Ebata K, Kondo T, Hiramine R, Aizawa T, Ogura Y, Hayashi T, Mori H, Kurokawa K, Tomizuka K, Ayabe T, Teshima T. J Exp Med. 2017 Dec 4;214(12):3507-3518. doi: 10.1084/jem.20170418. Epub 2017 Oct 24.
  31. Risk factors of human herpesvirus 6 encephalitis/myelitis after allogeneic hematopoietic stem cell transplantation. Miyashita N, Endo T, Onozawa M, Hashimoto D, Kondo T, Fujimoto K, Kahata K, Sugita J, Goto H, Matsukawa T, Hashino S, Teshima T. Transpl Infect Dis. 2017 Jun;19(3). doi: 10.1111/tid.12682. Epub 2017 Apr 12. PMID: 28207973
  32. Shimoji S, Hashimoto D, Tsujigiwa H, Miyawaki K, Kato K, Takahashi S, Ogasawara R, Jiromaru T, Iwasaki H, Miyamoto T, Akashi K, Teshima T. Graft-versus-host disease targets ovary and causes female infertility in mice. Blood. 2017 Mar 2;129(9): 1216-1225.
  33. Shiratori S, Kosugi-Kanaya M, Hayase E, Okada K, Goto H, Sugita J, Onozawa M, Nakagawa M, Kahata K, Hashimoto D, Endo T, Kondo T, Teshima T. T-cell depletion effects of low-dose antithymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation. Transpl Immunol. 2017 Nov 8; pii: S0966-3274(17)30111-9.
  34. Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance. Goldberg L, Gough SM, Lee F, Dang C, Walker RL, Zhu YJ, Bilke S, Pineda M, Onozawa M, Jo Chung Y, Meltzer PS, Aplan PD. Genes Chromosomes Cancer. 2017 Jun;56(6):472-483. doi: 10.1002/gcc.22451. Epub 2017 Mar 31. PMID: 28196408
  35. T-cell depletion effects of low-dose antithymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation. Shiratori S, Kosugi-Kanaya M, Hayase E, Okada K, Goto H, Sugita J, Onozawa M, Nakagawa M, Kahata K, Hashimoto D, Endo T, Kondo T, Teshima T. Transpl Immunol. 2017 Nov 8. pii: S0966-3274(17)30111-9. doi: 10.1016/j.trim.2017.11.001. [Epub ahead of print] No abstract available. PMID: 29128394

英文症例報告

  1. Computer-Aided Diagnosis of Focal Liver Lesions Using Contrast-Enhanced Ultrasonography With Perflubutane Microbubbles. Kondo S, Takagi K, Nishida M, Iwai T, Kudo Y, Ogawa K, Kamiyama T, Shibuya H, Kahata K, Shimizu C.
  2. Diffuse large B-cell lymphoma with a bulky mass in the cranial vault. Kanaya M, Endo T, Hashimoto D, Endo S, Takemura R, Okada K, Hatanaka KC, Matsuno Y, Teshima T. Int J Hematol. 2017 Aug;106(2):147-148, 2017 Apr 7.
  3. Disseminated toxoplasmosis after hematopoietic stem cell transplantation showing unusual magnetic resonance images. Tateno T, Onozawa M, Hashiguchi J, Ishio T, Yuzawa S, Matsuoka S, Kosugi-Kanaya M, Okada K Shiratori S, Goto H, Kimura T, Sugita J, Nakagawa M, Hashimoto D, Kahata K, Fujimoto K, Endo T, Kondo T, Tanaka S, Hashino S, Teshima T. Transpl Infect Dis. 2017 Aug;19(4). doi: 10.1111/tid.12720. Epub 2017 Jun 20.
  4. Kanaya M, Endo T, Hashimoto D, Endo S, Takemura R, Okada K, Hatanaka KC, Matsuno Y, Teshima T. Diffuse large B-cell lymphoma with a bulky mass in the cranial vault. Int J Hematol. 2017 Aug; 106(2): 147-148, 2017.
  5. Linear IgA Bullous Dermatosis Associated with Immunoglobulin Light-chain Amyloidosis. Yamaguchi Y, Ujiie H, Ohigashi H, Iwata H, Muramatsu K, Endou T, Teshima T, Shimizu H. Acta Derm Venereol. 2017 Apr 6;97(4):528-529. doi: 10.2340/00015555-2590. No abstract available. PMID: 27882389
  6. Miyakawa S, Ohe M, Shida H, Horita T, Furuya K, Hashino S: A case of adult-onset Still’s disease accompanied by pseudo-gray platelet syndrome. Blood Res 52, 231-233, 2017 Sep
  7. Myasthenia gravis after allogeneic bone marrow transplantation: A case report and literature review. Tsutsumi Y, Kamiishi T, Kikuchi R, Ito S, Matsuoka S, Teshima T. Hematol Oncol Stem Cell Ther. 2017 May 18. [Epub ahead of print]
  8. Ohe M, Hashino S, Shida H, Horita T, Sugiura M: A case of Waldenstrom’s macroglobulinemia treated using clarithromycin and prednisolone. Transl Clin Pharmacol 25, 134-137, 2017.

英文著書

  1. TGF-β Family Signaling in Ductal Differentiation and Branching Morphogenesis. Kahata K, Maturi V, Moustakas A. Cold Spring Harb Perspect Biol. 2017 Mar 13. pii: a031997. doi: 10.1101/cshperspect.a031997. [Epub ahead of print]
  2. TGF-β Family Signaling in Epithelial Differentiation and Epithelial-Mesenchymal Transition. Kahata K, Dadras MS, Moustakas A. Cold Spring Harb Perspect Biol. 2018 Jan 2;10(1). pii: a022194. doi: 10.1101/cshperspect.a022194. Review.

和文総説

  1. 移植後シクロホスファミドを用いた血縁者間HLA半合致移植法の開発. 豊嶋崇徳. 2016年度AMED 4事業合同成果報告会　pp42, 2017 Feb 24.
  2. 造血幹細胞移植アップデート. 豊嶋崇徳. 日本検査血液学会雑誌 18(3):441-447, 2017.
  3. 序〜HLA半合致移植の現状と展望〜. 豊嶋崇徳. 血液フロンティア 27(12):17-22, 2017.
  4. GVHDによる移植後不妊. 豊嶋崇徳. 血液内科75(5)656-660, 2017
  5. 【幹細胞システム】 造血幹細胞移植後のGVHDによる腸幹細胞とそのニッチ傷害に起因する腸管免疫システムの破綻(解説/特集)
    Author：早瀬 英子(北海道大学大学院医学研究院内科学分野血液内科), 豊嶋 崇徳
    Source： Clinical Calcium (0917-5857)27巻6号 Page829-833(2017.05)
  6. 移植後シクロホスファミドを用いたHLA半合致移植(解説)
    Author：杉田 純一(北海道大学 大学院医学研究院血液内科学教室)
    Source： 臨床血液 (0485-1439)58巻10号 Page2124-2134(2017.10)
  7. 各種薬剤を用いたHLA半合致移植　１）PTCy（posttransplant cyclophosphamide）HLA半合致移植 杉田純一 血液フロンティア　27巻12号 , 2017年11月 , pp.23-30
  8. 移植後シクロホスファミドを用いたHLA半合致移植 杉田純一・豊嶋崇徳 医学のあゆみ　263巻10号, 2017年12月, p863-864
  9. 同種造血幹細胞移植後の移植片対宿主病と卵巣機能不全の関連
    Author: 下地園子, 橋本大吾, 豊嶋崇徳
    Source: 臨床血液. 58 巻7 号: 827-834, 2017

和文原著

  1. 日本骨髄バンクドナーの２回骨髄提供に関する検討. 折原勝己, 吾郷浩厚, 奥山美樹, 落合亮一, 澤正史, 田野﨑隆二, 玉井佳子, 豊嶋崇徳, 中尾康夫, 日野雅之, 宮﨑泰司, 神田義伸, 金森平和. 日本造血細胞移植学会雑誌 Vol. 6 (2017) No. 2 p. 108-114, 2017
  2. 川原由佳子、吉村　彩、折戸智恵子、横田　卓、加納崇裕、本間理央、小西　剛、橋野　聡：子宮頸がん予防に関する葉酸などのリスク因子とその評価. CAMPUS HEALTH 54, 137-142, 2017.
  3. 武田弘子、齋藤暢一朗、斉藤美香、川島るい、大崎明美、石原可愛、藤井　泰、朝倉　聡、橋野　聡：大学で実施するPHQ-9の呼出基準についての考察〜質問項目９と合計得点〜. CAMPUS HEALTH 54, 149-154, 2017.
  4. 北海道HIV福祉サービスネットワークの構築(原著論文)
    Author：富田 健一(北海道大学病院/HIV診療支援センター), 白坂 るみ, 遠藤 知之, 渡部 恵子, 武内 阿味, 坂本 玲子, センテノ田村 恵子, 石田 陽子, 豊嶋 崇徳
    Source： 日本エイズ学会誌 (1344-9478)19巻3号 Page180-184(2017.08)

和文著書

  1. GVHDとTA-TMA. 豊嶋崇徳.（分担執筆） 血液疾患 最新の治療2017-2019.　南江堂. pp.296-301, 2017.
  2. 急性骨髄性白血病. 豊嶋崇徳.（分担執筆） 内科学第11版. 朝倉書店. pp.1983-1986, 2017.
  3. 移植片対宿主病. 豊嶋崇徳.（分担執筆） 病気とくすり2017基礎と実践Expert’s　Guide　南山堂　pp．262-268, 2017.
  4. 造血幹細胞移植とリンパ腫治療の最新情報について〜グループ・ネクサス・ジャパン医療セミナーより〜
    Author:後藤秀樹（北海道大学病院 血液内科）
    Source: nexus journal vol36 page2-15
  5. 橋野　聡：北海道における勤務医高齢化の特色. 「勤務医の過重労働を改善するために」北海道医師会勤務医部会報告16-22項、平成29年3月20日発行